A Consensus Conference on complex biologics and low molecular weight heparins

International Angiology

Volumn 29, Issue 2, 2010, Pages 193-196

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN;

AUTHORITY; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; PATIENT SAFETY; PEER REVIEW; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; PUBLIC HEALTH;

ANTICOAGULANTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS, PHASE III AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG APPROVAL; EUROPE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952807075     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101-161
2. Kalodiki E, Leong W. SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs). Clin Appl Thromb Hemost 2009;15:8-11.
3. Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J et al. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 2009;7:1222-1225
4. Gray E, Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost 2009;7:1218-1221
5. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):338S-400S.
6. Marcus P, Tapson VF, Groce JB, Patel G. Low molecular weight heparins: update on Follow-On "Generic" Compounds (Part 1). Chest Physician Jul 2009.
7. Marcus P, Tapson VF, Groce JB, Patel G. Low molecular weight heparins: update on Follow-On "Generic" Compaounds (Part 2) Chest Physician Aug 2009.
8. American College of Chest Physicians. Diagnosis and Management of Work-Related Asthma [Internet]. [Accessed 2010 Feb 28; cited 2010 March 9]. Available at: http://chestjournal.chestpubs.Org/content/134/3-suppl
9. Report of the 2007 APhA House of Delegates: actions of the official legislative body of the American Pharmacists Association. J Am Pharm Assoc (2003) 2007;47:580-582
10. European Medicines Agency. Human Medicines [Internet]. [Accessed 2010 Feb 20; cited 2010 March 9]. Available at: http://www.emea.europa.eu/index/indexhl. htm
11. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
12. Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30:1087-1092
13. Gastl GG, Geissler DK, Lang A, Ludwig H, Muller M, Sitte H. Austrian Society of Hematology and Oncology position paper on Biosimilars. Mag Europ Med Oncol 2009;2:232-233